Free public records show Zenas BioPharma (USA), LLC in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Zenas BioPharma (USA), LLC or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: SEC EDGAR, Company filings, CIK 1953926. Retrieved 13 Nov 2026.
6 active studies led by Zenas BioPharma (USA), LLC, of 10 in all
Source: ClinicalTrials.gov, Studies with Zenas BioPharma (USA), LLC (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1953926.
Studies Zenas BioPharma (USA), LLC leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Zenas BioPharma (USA), LLC or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Zenas BioPharma (USA), LLC: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Zenas BioPharma (USA), LLC is in.
Stories on the topics Zenas BioPharma (USA), LLC works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Behind every insurance claim is a standard electronic message. The CAQH Index says $20 billion a year could…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
ReadSearch all reports for Zenas BioPharma (USA), LLC All companies